Scotiabank Initiates Coverage On Vertex Pharmaceuticals with Sector Perform Rating, Announces Price Target of $480
Portfolio Pulse from Benzinga Newsdesk
Scotiabank has initiated coverage on Vertex Pharmaceuticals with a Sector Perform rating and set a price target of $480.
October 16, 2024 | 2:50 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Scotiabank has initiated coverage on Vertex Pharmaceuticals with a Sector Perform rating and a price target of $480, indicating a neutral outlook.
The Sector Perform rating suggests that the stock is expected to perform in line with the market. The price target of $480 provides a specific valuation benchmark, but the neutral rating indicates no strong buy or sell recommendation.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100